New oral anticoagulants: Will they replace warfarin?

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Volumn 113, Issue 5, 2012, Pages 575-580

  Little, James W ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862580788     PISSN: 22124403     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oooo.2011.10.006     Document Type: Review

References (30)

1. Weitz IC. Hemostasis, thrombosis, fibrinolysis and cardiovascular disease. In: Bonow RO, editor. Braunwald's heart disease: a textbook of cardiovascular medicine. 9th ed. Philadelphia: Saunders/ Elsevier; 2011. p. 1844-66.
2. FDA. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. Available at http://www.fda.gov/NewsEvents/ Newsroom/ PressAnnouncements/ucm230241.htm. Accessed November 9, 2011.
3. Walker EP. Panel recommends approval of rivaroxaban to prevent deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement: Medpage Today 2009.
4. Hurley D. FDA approval sought for rivaroxaban to prevent stroke in atrial fibrillation. Neurol Today 2011;11:22-3.
5. Knewitz E. New drug application submitted to FDA for rivaroxaban for prevention of stroke in patients with atrial fibrillation. Available at http://www.businesswire.com. Accessed April 23, 2011.
6. RXList. Dabigatran. Available at http://www.RXList.com. Accessed March 10, 2011.
7. Josephson SA. An update 12/9/2010: Dabigatran similar to warfarin in patients with history of stroke or transient ischemic attacks (TIA). In: Fauci AS, editor. Harrison's principles of internal medicine. 17th ed. New York McGraw-Hill; 2010.
8. Maegdefessel L, Spin JM, Azuma J, Tsao PS. New options with dabigatran etexilate in anticoagulant therapy. Vasc Health Risk Manag 2011;6:339-49.
9. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2011; 103:1116-27.
10. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011;49:761-72.
11. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-6.
12. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2011;376:975-83.
13. Dabigatran. In: Fauci AS, editor. Monographs D. New York: McGraw-Hill; 2011. Available at http://accessmedicine.com/ drugcontent/dabigatran. Accessed May 1, 2011.
14. Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2011;3:652-60.
15. Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism-systematic review and adjusted indirect comparison. J Clin Pharm Ther 2011;36:111-24.
16. Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011;105:444-53.
17. Cleland JG, Coletta AP, Buga L, Antony R, Pellicori P, Freemantle N, et al. Clinical trials update from the American Heart Association meeting 2010: eMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. Eur J Heart Fail 2011;13:460-5.
18. Dagres N, Sommer P, Anastasiou-Nana M, Hindricks G. Treating arrhythmias: an expert opinion. Expert Opin Pharmacother 2011.
19. Wolfram O, Hammwoehner M, Gramley F, Goette A. Update on pharmacologic approaches to prevent thromboembolism in atrial fibrillation: are thrombin and factor Xa inhibitors the ultimate answer? Curr Vasc Pharmacol 2011.
20. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133-9.
21. Samama MM, Martinoli J, LeFlem L, Guinet C, Plu-Bureau G, Depassse F, et al. Assessment of laboratory assays to measure rivaroxaban-an oral direct factor Xa inhibitor. Thromb Haemost 2010;103:1-10?.
22. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010;32:673-9.
23. Rivaroxaban. In: Fauci AS, editor. Monographs D. New York: McGraw-Hill; 2011. Available at http://accessmedicine.com/ drugcontent/rivaroxaban. Accessed April 30, 2011.
24. Little JW, Falace DA, Miller CS, Rhodus NL. Dental management of the medically compromised patient. 8th ed. St. Louis: Mosby/Elsevier; 2012.
25. Little JW, Falace DA, Miller CS, Rhodus NL. Bleeding disorders. In: Little JW, Falace DA, Miller CS, Rhodus NL. Dental management of the medically compromised patient. 7th ed. St. Louis: Elsevier; 2008. p. 396-433.
26. Harbrecht U. Old and new anticoagulants. Hamostaseologie 2011;31:21-7.
27. Mannucci PM, Franchini M. Old and new anticoagulant drugs: a minireview. Ann Med 2011;43:116-23.
28. Mousa SA. Novel anticoagulant therapy: principle and practice. Methods Mol Biol 2011;663:157-79.
29. Siddiqui FM, Qureshi AI. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. Expert Opin Pharmacother 2011;11:1403-11.
30. Verma AK. Dabigatran etexilate: a new thrombin inhibitor. Med J Aust 2011;192:407-12.